Neuro-All February 2014

neuro-all@lists.umanitoba.ca

2 participants
4 discussions

by Kelly Jorundson

Everyone is invited to attend! Manitoba Neuroscience Network Seminar Series Friday, February 28th, 2014 9:00 am PX236/238 PsychHealth Bldg. Dr. V. Wee Yong<http://www.ucalgary.ca/dcns/experimental/members/Yong> Professor, Canada Research Chair in Nueroimmunology Hotchkiss Brain Institute and Department of Clinical Neurosciences and Oncology University of Calgary Topic: Overcoming inhibitors in the lesion microenvironment for CNS regeneration. Biosketch: Dr. V. Wee Yong is a Professor at the Hotchkiss Brain Institute and the Departments of Clinical Neurosciences and Oncology at The University of Calgary. He co-directs the Multiple Sclerosis (MS) Program of the Hotchkiss Brain Institute, providing the basic science leadership, and he holds the Canada Research Chair in Neuroimmunology. Dr. Yong received his Ph.D. from the University of British Columbia, Vancouver, and started his faculty appointment at the Montreal Neurological Institute, McGill University, in 1989. He located to Calgary in 1996. Dr. Yong's research interests lie in the area of neuroimmunology, neuroprotection and CNS regeneration, and his projects have been guided by MS, spinal cord injury and malignant gliomas. Dr. Yong has published 230 peer-reviewed manuscripts and his research has been translated into clinical trials in MS and spinal cord injury. His work has been cited over 12,000 times by other authors in scientific publications. In 2003, Dr. Yong was awarded the Queen's Golden Jubilee Year Medallion for volunteer activities on behalf of the MS Society of Canada. In 2010, Dr. Yong was elected a fellow of the Canadian Academy of Health Sciences, a top honor for those working in the medical sciences. Dr. Yong is the immediate past chair of the Medical Advisory Committee of the MS Society of Canada, he directs the Alberta endMS Regional Research and Training Center, and he is on the editorial board of 7 international journals. In 2012, Dr. Yong was elected by an international community to be the Vice President of the International Society of Neuroimmunology; he will become its President in 2014. Brief description of research interests: Neuroimmunology is the study of inflammation in the nervous system. Virtually all neurological disorders have inflammatory components, and these include diseases traditionally associated with overt inflammation, such as multiple sclerosis (MS), and those previously thought to be purely degenerative, including Alzheimer's disease. Neuroinflammation originates from the trafficking of several leukocyte subsets into the nervous system and through the production of immune molecules by neural cells themselves. The interaction between leukocytes and neural cells further promotes neuroinflammation and injury. In recent years, reparative properties of neuroinflammation have been appreciated, so that the balance between beneficial and detrimental neuroinflammation is a crucial determinant of outcome. My research projects have been guided by 3 diseases of the central nervous system (CNS): MS, spinal cord injury (SCI) and brain tumors (malignant gliomas). MS and SCI provide my research program with diseases of chronic and acute neuroinflammation, respectively. In contrast, malignant gliomas present a disease of immunosuppression, whereby the cancer cells neutralize the activity of leukocytes that infiltrate into these tumors. My research has been translated into clinical trials in MS and in spinal cord injury. Collectively, my studies of neuroimmunology are aimed at understanding, controlling and tipping the balance of neuroinflammation towards one of neuroprotection and regeneration from CNS insults. Presented in co-operation with University of Manitoba Clinical Neuroscience Rounds ************************************** Division of Neurodegenerative Disorders, St. Boniface Hospital Research Neuroscience Seminar Series Friday, February 28th2014 12:00 Noon 500 John Buhler Research Centre - Bannatyne Campus Dr. Bruce Perkins<http://www.uhnresearch.ca/researchers/profile.php?lookup=7067> Associate Professor, Division of Endocrinology and Metabolism University of Toronto & Clinician Scientist, Lunenfeld Tanenbaum Research Institute, Leadership Sinai Centre for Diabetes, Mount Sinai Hospital Topic: The Identification of Diabetic Neuropathy in type 1 Diabetes Biosketch: Bruce A Perkins, MD MPH is Associate Professor and Endocrinologist at the University of Toronto, and a Diabetes Complications Clinician-Scientist. He obtained his MD and Internal Medicine training at the University of Toronto, his endocrinology subspecialty training at Harvard University, his Masters of Public Health in Epidemiology at the Harvard School of Public Health, and a research fellowship in epidemiology at the Joslin Diabetes Center. In 2003 he was appointed at the Toronto General Hospital and earned a Canadian Diabetes Association early career personnel award for his work in diabetic neuropathy. His clinical practice has focused on type 1 diabetes management, and he directed the formation of an insulin pump program at the UHN. His research work has focused on clinical biomarkers for the early stages of diabetes complications using longitudinal cohort methods as well as clinical trials. Highlights are "Early GFR Loss" as a predictive marker for risk of advanced kidney disease using serial cystatin C analysis and the concept of in-vivo Corneal Confocal Microscopy as a method to analyze the small fiber morphological abnormalities that predict diabetic neuropathy. His clinical trial work in insulin pump and continuous glucose monitoring interventions has contributed to refinements in type 1 diabetes care. He is active on national and international diabetes clinical practice guideline committees including Microvascular Chair on the CDA's 2013 Clinical Practice Guidelines Steering Committee. He has received funding from the Juvenile Diabetes Research Foundation, Canadian Diabetes Association, CIHR, and the Banting and Best Diabetes Center and is a member of the JDRF's Canadian Clinical Trial Network. He is initiating a JDRF-funded nation-wide cohort study to determine factors associated with longevity in type 1 diabetes. Presented in co-operation with Manitoba Institute of Child Health Kelly Jorundson Winnipeg Chapter Society for Neuroscience R4046 - 351 Tache Avenue Winnipeg, MB R2H 2A6 Email: wcsn(a)sbrc.ca<mailto:wcsn@sbrc.ca> Website: www.sfn-manitoba.ca<http://www.sfn-manitoba.ca>

10 years, 2 months

Rick Hansen Institute Funding: Call for Proposals

by Winnipeg Chapter Society for Neuroscience

---------------------------------- Rick Hansen Institute Call for Proposals RHI is accepting applications for funding requests pertaining to projects related to Emerging Interventions & Innovative Technologies and Preclinical SCI Research Towards Cures. Application deadline: April 30, 2014 For more information http://www.rickhanseninstitute.org/open-funding-rfa Questions contact: Phalgun Joshi, PhD Managing Director, Program Operations & Support t: 604-827-1673 e: pjoshi(a)rickhanseninstitute.org John Barclay, MBA Manager, Commercialization & Industry Relations t: 604-827-1676 e: jbarclay(a)rickhanseninstitute.org <mailto:jbarclay@rickhanseninstitute.org> Kelly Jorundson Winnipeg Chapter Society for Neuroscience R4046 - 351 Tache Avenue Winnipeg, MB R2H 2A6 Tel: 204.235.3939 Fax: 204.237.4092 Email: kjorund(a)sbrc.ca OR kjorund(a)yahoo.ca Website: www.sfn-manitoba.ca

10 years, 2 months

Your input is important and appreciated

by Winnipeg Chapter Society for Neuroscience

Dear Neuroscientists, We have started to plan the Manitoba Neuroscience Network - 2014 Annual Meeting and are again looking into the possibility of holding a Retreat-style meeting mid-end of June, held over 2 days, at a site within two hours drive (e.g. Whiteshell, Kenora etc.) where a stay overnight would be encouraged (to enhance team building!). Our main focus for this year will be to feature new staff's research, with a secondary focus on promoting interests in establishing research teams (ideally linking CIHR pillars 1 and 2). Therefore, we encourage attendance from researchers in the basic and clinical realms. By at least getting pillars 1 and 2 to communicate at some point in the future we could then identify possible staff in pillars 3 and 4 at UofM (or elsewhere). And then we have the basis for competitive team grants with a strong UofM flavor. Could those that would potentially attend a retreat-style meeting in mid-end June, held over 2 days at a site ~2 hrs drive away (e.g. Whiteshell, etc), please respond ASAP so we can start planning. Regards, Paul Paul Fernyhough Program Chair - Manitoba Neuroscience Network 2014 Annual Meeting Director, Division of Neurodegenerative Disorders, St. Boniface Research Centre Professor, Departments of Pharmacology & Therapeutics, Physiology University of Manitoba Kelly Jorundson Winnipeg Chapter Society for Neuroscience R4046 - 351 Tache Avenue Winnipeg, MB R2H 2A6 Tel: 204.235.3939 Fax: 204.237.4092 Email: kjorund(a)sbrc.ca OR kjorund(a)yahoo.ca Website: www.sfn-manitoba.ca

10 years, 2 months

upcoming seminars

by Winnipeg Chapter Society for Neuroscience

Everyone is invited to attend! Manitoba Neuroscience Network Seminar Series Friday, February 28th, 2014 9:00 am PX236/238 PsychHealth Bldg. Dr. V. Wee Yong <http://www.ucalgary.ca/dcns/experimental/members/Yong> Professor, Canada Research Chair in Nueroimmunology Hotchkiss Brain Institute and Department of Clinical Neurosciences and Oncology University of Calgary Topic: Overcoming inhibitors in the lesion microenvironment for CNS regeneration. Biosketch: Dr. V. Wee Yong is a Professor at the Hotchkiss Brain Institute and the Departments of Clinical Neurosciences and Oncology at The University of Calgary. He co-directs the Multiple Sclerosis (MS) Program of the Hotchkiss Brain Institute, providing the basic science leadership, and he holds the Canada Research Chair in Neuroimmunology. Dr. Yong received his Ph.D. from the University of British Columbia, Vancouver, and started his faculty appointment at the Montreal Neurological Institute, McGill University, in 1989. He located to Calgary in 1996. Dr. Yong's research interests lie in the area of neuroimmunology, neuroprotection and CNS regeneration, and his projects have been guided by MS, spinal cord injury and malignant gliomas. Dr. Yong has published 230 peer-reviewed manuscripts and his research has been translated into clinical trials in MS and spinal cord injury. His work has been cited over 12,000 times by other authors in scientific publications. In 2003, Dr. Yong was awarded the Queen's Golden Jubilee Year Medallion for volunteer activities on behalf of the MS Society of Canada. In 2010, Dr. Yong was elected a fellow of the Canadian Academy of Health Sciences, a top honor for those working in the medical sciences. Dr. Yong is the immediate past chair of the Medical Advisory Committee of the MS Society of Canada, he directs the Alberta endMS Regional Research and Training Center, and he is on the editorial board of 7 international journals. In 2012, Dr. Yong was elected by an international community to be the Vice President of the International Society of Neuroimmunology; he will become its President in 2014. Brief description of research interests: Neuroimmunology is the study of inflammation in the nervous system. Virtually all neurological disorders have inflammatory components, and these include diseases traditionally associated with overt inflammation, such as multiple sclerosis (MS), and those previously thought to be purely degenerative, including Alzheimer's disease. Neuroinflammation originates from the trafficking of several leukocyte subsets into the nervous system and through the production of immune molecules by neural cells themselves. The interaction between leukocytes and neural cells further promotes neuroinflammation and injury. In recent years, reparative properties of neuroinflammation have been appreciated, so that the balance between beneficial and detrimental neuroinflammation is a crucial determinant of outcome. My research projects have been guided by 3 diseases of the central nervous system (CNS): MS, spinal cord injury (SCI) and brain tumors (malignant gliomas). MS and SCI provide my research program with diseases of chronic and acute neuroinflammation, respectively. In contrast, malignant gliomas present a disease of immunosuppression, whereby the cancer cells neutralize the activity of leukocytes that infiltrate into these tumors. My research has been translated into clinical trials in MS and in spinal cord injury. Collectively, my studies of neuroimmunology are aimed at understanding, controlling and tipping the balance of neuroinflammation towards one of neuroprotection and regeneration from CNS insults. Presented in co-operation with University of Manitoba Clinical Neuroscience Rounds ************************************** Division of Neurodegenerative Disorders, St. Boniface Hospital Research Neuroscience Seminar Series Friday, February 28th2014 12:00 Noon 500 John Buhler Research Centre - Bannatyne Campus Dr. Bruce Perkins <http://www.uhnresearch.ca/researchers/profile.php?lookup=7067> Associate Professor, Division of Endocrinology and Metabolism University of Toronto & Clinician Scientist, Lunenfeld Tanenbaum Research Institute, Leadership Sinai Centre for Diabetes, Mount Sinai Hospital Topic: The Identification of Diabetic Neuropathy in type 1 Diabetes Biosketch: Bruce A Perkins, MD MPH is Associate Professor and Endocrinologist at the University of Toronto, and a Diabetes Complications Clinician-Scientist. He obtained his MD and Internal Medicine training at the University of Toronto, his endocrinology subspecialty training at Harvard University, his Masters of Public Health in Epidemiology at the Harvard School of Public Health, and a research fellowship in epidemiology at the Joslin Diabetes Center. In 2003 he was appointed at the Toronto General Hospital and earned a Canadian Diabetes Association early career personnel award for his work in diabetic neuropathy. His clinical practice has focused on type 1 diabetes management, and he directed the formation of an insulin pump program at the UHN. His research work has focused on clinical biomarkers for the early stages of diabetes complications using longitudinal cohort methods as well as clinical trials. Highlights are "Early GFR Loss" as a predictive marker for risk of advanced kidney disease using serial cystatin C analysis and the concept of in-vivo Corneal Confocal Microscopy as a method to analyze the small fiber morphological abnormalities that predict diabetic neuropathy. His clinical trial work in insulin pump and continuous glucose monitoring interventions has contributed to refinements in type 1 diabetes care. He is active on national and international diabetes clinical practice guideline committees including Microvascular Chair on the CDA's 2013 Clinical Practice Guidelines Steering Committee. He has received funding from the Juvenile Diabetes Research Foundation, Canadian Diabetes Association, CIHR, and the Banting and Best Diabetes Center and is a member of the JDRF's Canadian Clinical Trial Network. He is initiating a JDRF-funded nation-wide cohort study to determine factors associated with longevity in type 1 diabetes. Presented in co-operation with Manitoba Institute of Child Health Kelly Jorundson Administrative Manager, Division of Neurodegenerative Disorders St. Boniface Hospital Research & Department of Pharmacology & Therapeutics University of Manitoba Room R4046 - 351 Taché Avenue Winnipeg, MB R2H 2A6 CANADA Tel: 204.235.3939 Fax: 204.237.4092 Email: kjorund(a)sbrc.ca OR kjorund(a)yahoo.ca Website: www.sbrc.ca/dnd OR www.umanitoba.ca/medicine/units/pharmacology

10 years, 2 months

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

Neuro-All February 2014